Skip to main content

Liver Diseases

The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.

Publications

Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection.

PMID: 34950863
Journal: JHEP reports : innovation in hepatology
Year: 2022
Reference: JHEP Rep. 2021 Oct 24;4(1):100388. doi: 10.1016/j.jhepr.2021.100388. eCollection 2022 Jan.
Impact factor: 0
Publication type: Paper in international publication
Authors: Fletcher, Simon P; van Buuren, Nicholas; Ramirez, Ricardo; Turner, Scott; Chen, Diana; Suri, Vithika; Aggarwal, Abhishek; Moon, Christina; Kim, Sam; Kornyeyev, Dmytro et al.
DOI: 10.1016/j.jhepr.2021.100388

A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain).

PMID: 34842496
Journal: Emerging Microbes & Infections
Year: 2022
Reference: Emerg Microbes Infect. 2022 Dec;11(1):172-181. doi: 10.1080/22221751.2021.2011617.
Impact factor: 7.163
Publication type: Paper in international publication
Authors: Andres, Cristina; Pinana, Maria; Borras-Bermejo, Blanca; Gonzalez-Sanchez, Alejandra; Garcia-Cehic, Damir; Esperalba, Juliana; Rando, Ariadna; Zules-Ona, Ricardo-Gabriel; Campos, Carolina; Codina, Maria Gema et al.
DOI: 10.1080/22221751.2021.2011617

Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis.

PMID: 34989164
Journal: Hepatology Communications
Year: 2022
Reference: Hepatol Commun. 2022 Jun;6(6):1392-1402. doi: 10.1002/hep4.1889. Epub 2022 Jan 6.
Impact factor: 5.073
Publication type: Paper in international publication
Authors: Gratacos-Gines, Jordi; Tellez, Luis; Gomez-Outomuro, Ana; Navascues, Carmen A; Riveiro-Barciela, Mar; Vinuesa, Raquel; Gomez-Camarero, Judith; Garcia-Retortillo, Montserrat; Diaz-Fontenla, Fernando; Salcedo, Magdalena et al.
DOI: 10.1002/hep4.1889

Reconciling short-term clinical and Immunological outcomes of SARS-CoV-2 vaccination in Solid Organ Transplant recipients.

PMID: 34554648
Journal: AMERICAN JOURNAL OF TRANSPLANTATION
Year: 2022
Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5.
Impact factor: 8.086
Publication type: Letter or abstract
Authors: Toapanta, Nestor; Esperalba, Juliana; Campos-Varela, Isabel; Pont, Teresa; Len, Oscar; Campins, Magda; Moreso, Francesc; Crespo, Elena; Munoz, Marina; Lopez, Manuel et al.
DOI: 10.1111/ajt.16855

Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B.

PMID: 34041466
Journal: JHEP reports : innovation in hepatology
Year: 2021
Reference: JHEP Rep. 2021 Mar 17;3(3):100280. doi: 10.1016/j.jhepr.2021.100280. eCollection 2021 Jun.
Impact factor: 0
Publication type: Paper in international publication
Authors: Buti, Maria, Stepanova, Maria, Palom, Adriana, Riveiro-Barciela, Mar, Nader, Fatema, Roade, Luisa, Esteban, Rafael, Younossi, Zobair et al.
DOI: 10.1016/j.jhepr.2021.100280

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.

PMID: 34014280
Journal: Disease Models & Mechanisms
Year: 2021
Reference: Dis Model Mech. 2021 May 1;14(5). pii: 268318. doi: 10.1242/dmm.048884. Epub 2021 May 20.
Impact factor: 5.758
Publication type: Paper in international publication
Authors: Bravo, Miren, Raurell, Imma, Barbera, Aurora, Hide, Diana, Gil, Mar, Estrella, Federico, Salcedo, Maria Teresa, Augustin, Salvador, Genesca, Joan, Martell, Maria et al.
DOI: 10.1242/dmm.048884

Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects.

PMID: 33880971
Journal: EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Year: 2021
Reference: Expert Rev Mol Diagn. 2021 Apr;21(4):381-396. doi: 10.1080/14737159.2021.1913055. Epub 2021 Apr 21.
Impact factor: 5.225
Publication type: Review in international publication
Authors: Garcia-Garcia, Selene, Cortese, Maria Francesca, Rodriguez-Algarra, Francisco, Tabernero, David, Rando-Segura, Ariadna, Quer, Josep, Buti, Maria, Rodriguez-Frias, Francisco et al.
DOI: 10.1080/14737159.2021.1913055

PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.

PMID: 33227350
Journal: JOURNAL OF HEPATOLOGY
Year: 2021
Reference: J Hepatol. 2021 May;74(5):1097-1108. doi: 10.1016/j.jhep.2020.11.019. Epub 2020 Nov 20.
Impact factor: 25.083
Publication type: Paper in international publication
Authors: Francoz, Claire, Piano, Salvatore, Berg, Thomas, Bruns, Tony, Danielsen, Karen Vagner, Coenraad, Minneke, Merli, Manuela, Stauber, Rudolf, Zoller, Heinz, Ramos, Jose Presa et al.
DOI: 10.1016/j.jhep.2020.11.019

Blog

News

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Estudi sobre els patrons de consum habitual de l'alcohol en població jove

Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.

Més informació